Brooklyn ImmunoTherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2023

Eterna Therapeutics Inc.

(Exact Name of Registrant as Specified in its Charter)

Registrant’s telephone number, including area code: (212) 582-1199

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

 

On November 14, 2023, Eterna Therapeutics Inc., a Delaware corporation (the “Company”), entered into an Exclusive Amended and Restated License Agreement (the “A&R Agreement”) with Factor Bioscience Limited (“Factor”) to replace in its entirety the Exclusive License Agreement dated February 20, 2023, as amended on July 12, 2023.  The A&R Agreement provides for, among other things, the expansion of the Company’s license rights to include (i) know-how that is necessary or reasonably useful to practice to the licensed patents and (ii) the ability to sublicense through multiple tiers (as opposed to only permitting a direct sublicense).  The A&R Agreement also provides for technology transfer to Eterna, subject to the use restrictions in the A&R Agreement and reduces the termination rights of Factor under the A&R Agreement.

Dr. Matthew Angel, the Company’s President and Chief Executive Officer, is the co-founder, President, CEO, and a director of Factor Bioscience Inc., which is the parent of Factor.

The foregoing description of the A&R Agreement is only a summary and is qualified in its entirety by reference to the full text of the A&R Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 1.01*.

 

(d) Exhibits.

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

---